10-Q: ENDRA Life Sciences Narrows Loss, Eyes Crypto Strategy

ENDRA Life Sciences reported a significantly reduced net loss in the first half of 2025, while announcing a new, unproven cryptocurrency treasury strategy and ongoing capital needs.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $2,262,242 from $5,004,853 in the same period of 2024, representing a 55% improvement.
• Operating expenses significantly declined by 45% to $2,770,372 for the first half of 2025, down from $5,011,394 in the prior year.
• Research and development expenses decreased by 48% to $909,746, as the company shifts focus from product development to clinical trials and commercialization.
• Sales and marketing expenses fell by 66% to $137,825 due to a restructuring in the second quarter of 2024.
• General and administrative expenses decreased by 40% to $1,722,801.
• Cash used in operating activities for the six months ended June 30, 2025, was $2,406,844, an improvement from $4,227,613 in the prior year.
• Cash balance as of June 30, 2025, was $1,808,574, down from $3,229,480 at December 31, 2024.
• The company has an accumulated deficit of $105,700,341 as of June 30, 2025.
• No revenue has been generated from the TAEUS technology as of June 30, 2025.
• The Board authorized a cryptocurrency treasury strategy in July 2025, retaining Anchorage Digital Bank and Arca Investment Management, and forming a Cryptocurrency Advisory Board.
• The cryptocurrency strategy has not yet been implemented, and no cryptocurrency has been acquired.
• The company continues to face substantial doubt about its ability to continue as a going concern, requiring additional financing.

Sentiment

Score: 3

Explanation: While the company reduced its net loss and operating expenses, it remains pre-revenue with a significant accumulated deficit and a declining cash balance. The explicit 'going concern' warning and identified material weakness in internal controls are major concerns. The new, unproven cryptocurrency strategy adds a layer of speculative risk to an already high-risk profile, outweighing the positive cost reductions.

Positives

• Net loss significantly reduced by 55% for the six months ended June 30, 2025, compared to the same period in 2024.
• Operating expenses decreased substantially across all categories (R&D, Sales & Marketing, G&A), reflecting cost management and a shift in development focus.
• Cash used in operating activities decreased, indicating more efficient use of capital despite ongoing losses.
• The company is progressing towards clinical trials and commercialization of its TAEUS product, shifting from initial development.

Negatives

• The company has not generated any revenue from its TAEUS technology to date.
• Cash balance decreased from $3,229,480 at December 31, 2024, to $1,808,574 at June 30, 2025.
• An accumulated deficit of $105,700,341 highlights a long history of losses.
• The company faces substantial doubt about its ability to continue as a going concern without additional financing.
• A material weakness in internal control over financial reporting was identified due to insufficient personnel resources for segregation of duties.

Risks

• Limited commercial experience, limited cash, and a history of losses pose significant financial challenges.
• Inability to obtain adequate financing could force delays, reductions, or cessation of product development and commercialization efforts.
• Uncertainty in achieving profitability and market acceptance of the TAEUS technology.
• Potential for negative or inconclusive results from human studies.
• Reliance on collaborations and strategic alliances for development.
• Intense competition in the industry.
• Challenges in protecting intellectual property.
• Potential changes in healthcare industry regulations or third-party reimbursement practices.
• Delays and changes in regulatory requirements, including FDA and CE mark approvals.
• Risk of not regaining or maintaining compliance with Nasdaq Capital Market listing standards.
• The newly authorized cryptocurrency treasury strategy is unproven and has not yet been implemented, introducing new, speculative risks.
• Insufficient personnel resources within the accounting function leading to a material weakness in internal control over financial reporting.

Future Outlook

The company is developing a thermo-acoustic medical device (TAEUS) for accurate liver fat measurement, targeting metabolic disease detection and GLP-1 drug eligibility. The business model is expected to be primarily subscription-based with monthly recurring revenue, alongside traditional product sales. Regulatory approvals in the European Union and the United States are required before commercialization. The company plans to staff sales efforts upon FDA approval for the NAFLD TAEUS device and anticipates continued significant expenses for engineering design, inventory acquisition, regulatory filings (including clinical studies for de novo FDA application), marketing expansion, and development of other TAEUS applications. Future cash needs are expected to be financed through equity offerings, debt, or collaborations, as existing cash is insufficient for full commercialization.

Management Comments

• We are developing a thermo-acoustic medical device designed specifically for accurate liver fat measurement for metabolic disease detection and management and GLP-1 drug eligibility and management.
• Our goal is to create the next-generation enhanced ultrasound technology platform designed to establish key biomarkers for metabolic diseases management and emerging GLP-1 therapies.
• Our business model will primarily be a low barrier-to-entry, multi-year, subscription-based business model with monthly recurring revenue (MRR), while also offering a traditional product sale with annual upgrade and maintenance fees.
• We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of TAEUS and pursue FDA approval of the NAFLD TAEUS system.
• At this time, due to the inherently unpredictable nature of clinical development and regulatory approvals, we are unable to estimate with certainty the costs we will incur and the timelines we will require in our continued development efforts.
• We plan to begin staffing our sales efforts once we have obtained FDA approval for the sale of the NAFLD TAEUS device.
• In the absence of immediate additional liquidity, we will be forced to delay or reduce our product development programs and commercialization efforts, materially curtail or cease our operations, sell or dispose of our rights or assets, pursue sale or other strategic transactions, or undergo restructuring or insolvency proceedings.
• We will need to raise additional capital in order to fund operations through the next twelve months, and prior to any ability to fund operations from revenue generated from the sale of our products.
• Management intends to implement measures during 2025, as the company's resources and financial means allow, to remediate the material weakness in internal control, including adding additional accounting personnel or outside consultants and continuing the development of adequate written accounting policies and procedures.

Industry Context

The company operates in the medical device and biotech sector, specifically focusing on non-invasive diagnostic tools for metabolic diseases like NAFLD/NASH and supporting GLP-1 therapies. This area is experiencing significant growth due to the global obesity and diabetes epidemics and the rise of GLP-1 drugs. The company's strategy to offer a subscription-based model aligns with a broader industry trend towards recurring revenue models in healthcare technology. The pursuit of FDA and CE mark approvals is standard for medical devices, indicating a focus on established markets. The new cryptocurrency treasury strategy is highly unusual for a medical device company and deviates significantly from typical industry financial management practices, potentially signaling a high-risk approach to liquidity management.

Comparison to Industry Standards

• The company's pre-revenue status and accumulated deficit of over $105 million are common for early-stage biotech and medical device companies engaged in long development cycles and regulatory processes.
• The significant reduction in operating expenses and net loss indicates effective cost control, which is positive, but the absence of revenue means it cannot be compared to revenue-generating peers.
• The going concern warning is a critical red flag, typical for companies with limited cash and no established revenue stream, and is a standard disclosure for such financial conditions.
• The adoption of a cryptocurrency treasury strategy is highly unconventional for a medical device company and introduces a unique, unquantifiable risk profile not typically seen in comparable companies focused on medical device development, such as those developing ultrasound or imaging technologies (e.g., GE Healthcare, Philips, Siemens Healthineers, or smaller diagnostic imaging startups).
• The identified material weakness in internal controls regarding segregation of duties is a governance concern that is below industry best practices for public companies, regardless of size.

Management Changes

Corporate Governance

Legal Proceedings

• No legal matters that management believes would have a material effect on the company's financial position or results of operations as of June 30, 2025.

Related Party Transactions

• The company uses IS Bookkeeping & Payroll, a division of Impact Solve, LLC (dba Impact Solutions), an accounting and CFO service firm. The company's CFO, Richard Jacroux, works in a part-time capacity through Impact Solutions.
• Services provided by Impact Solutions and IS Bookkeeping & Payroll totaled $27,121 for the three months ended June 30, 2025, and $63,097 for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future equity raises, potential for stock price volatility due to going concern issues and the speculative cryptocurrency strategy, and uncertainty regarding the company's ability to achieve profitability.
• Employees: Potential for job insecurity if the company fails to secure additional financing and is forced to curtail operations. Equity compensation (options, RSUs) value is tied to stock performance and company viability.
• Customers (future): Potential for delays in product availability (TAEUS system) if financing is not secured, impacting their ability to utilize the technology for metabolic disease management and GLP-1 therapies.
• Creditors: Face increased risk due to the company's going concern status and reliance on future capital raises to meet obligations.
• Suppliers: May face payment delays or reduced orders if the company's financial condition deteriorates.

Next Steps

• Continue development of the TAEUS technology and pursue FDA approval for the NAFLD TAEUS system.
• Conduct clinical studies to advance the de novo application with the FDA.
• Hire a small internal marketing team to engage and support channel partners and clinical customers for the NAFLD TAEUS application.
• Expand marketing of the NAFLD TAEUS application.
• Advance development of other TAEUS applications.
• Add operational, financial, and management information systems and personnel.
• Raise additional capital through sales of equity securities, borrowing, or corporate collaborations to fund operations and commercialization.
• Implement measures to remediate the material weakness in internal control over financial reporting, including potentially adding accounting personnel or consultants and developing written policies.

Key Dates

Recommendation

The company faces severe liquidity challenges, evidenced by a declining cash balance and an explicit 'going concern' warning, indicating a high probability of needing substantial additional capital to continue operations. Despite reduced losses, the absence of any revenue from its core product, coupled with a significant accumulated deficit, highlights a fundamental lack of sustainable operations. The disclosed material weakness in internal controls raises serious concerns about financial reporting reliability. Furthermore, the highly speculative and unproven cryptocurrency treasury strategy introduces an additional layer of significant, non-core risk. Given these factors, the company's ability to execute its business plan and achieve profitability is highly uncertain, making it a high-risk investment with substantial downside potential.

Keywords

Medical Device, Liver Fat Measurement, TAEUS, Thermo-Acoustic Ultrasound, Metabolic Disease, GLP-1, NASH, MASH, FDA Approval, Biotech, Healthcare Technology, Quarterly Report, SEC Filing, Going Concern, Capital Raise, Cryptocurrency Strategy